Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Merck, AstraZeneca Reach Deal on Cancer Treatment

By Pharmaceutical Processing | September 11, 2013

WHITEHOUSE STATION, N.J. (AP) — AstraZeneca PLC will take over clinical development of a potential ovarian cancer treatment from Merck & Co. under a new licensing deal the drugmakers announced Wednesday.

As part of the deal, London-based AstraZeneca will pay Merck $50 million upfront and possible future payments tied to development and regulatory milestones as well as sales. AstraZeneca will be responsible for manufacturing and marketing the drug, along with development. Merck is based in Whitehouse Station, N.J.

The experimental drug, labeled MK-1775, is in mid-stage clinical testing as a possible oral treatment for certain forms of ovarian cancer when used with other therapies. It is designed to cause some tumor cells to divide without undergoing normal DNA repair processes. That sequence of events leads to the death of the tumor cells.

Shares of Merck closed at $47.98 in Tuesday trading and have climbed 17 percent so far this year. U.S.-traded shares of AstraZeneca closed at $49.57 and have booked a 5 percent gain in 2013.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE